Compile Data Set for Download or QSAR
Report error Found 226 Enz. Inhib. hit(s) with all data for entry = 11765
TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645376(US20240018122, Example 2 | N-(4-{[6-(5-chloro-2- f...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645385(US20240018122, Example 7 | N-(4-{[6-(5-chloro-2- f...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645387(US20240018122, Example 8 | N-(4-{[6-(5-chloro-2- f...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645411(US20240018122, Example 11 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645412(US20240018122, Example 15 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645413(US20240018122, Example 16 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645414(US20240018122, Example 18 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645415(US20240018122, Example 31 | 3-(4-acetylpiperazin-1...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645416(US20240018122, Example 33 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645417(US20240018122, Example 44 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645418(US20240018122, Example 65 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645419(US20240018122, Example 74 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645420(US20240018122, Example 76 | 3-[4-(2-aminoethyl)pip...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645421(US20240018122, Example 78 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645422(US20240018122, Example 79 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645423(US20240018122, Example 80 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645424(US20240018122, Example 82 | methyl N-[2-(4-{2-[(4-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645425(US20240018122, Example 83 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645426(US20240018122, Example 84 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645427(US20240018122, Example 85 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645428(US20240018122, Example 91 | methyl 4-{2-[(4-{[6-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645429(US20240018122, Example 92 | 4-(3-((4-((6-(5-chloro...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645430(US20240018122, Example 93 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645431(US20240018122, Example 94 | methyl 4-{2-[(4-{[6-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645432(US20240018122, Example 95 | 4-{2-[(4-{[6-(5-chloro...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645433(US20240018122, Example 96 | methyl 2-(4-{[(4-{[6-(...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645434(US20240018122, Example 97 | methyl 2-(4-{2-[(4-{[6...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645435(US20240018122, Example 98 | methyl 2-(4-{2-[(4-{[6...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645436(US20240018122, Example 99 | methyl 1-{2-[(4-{[6-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645437(US20240018122, Example 101 | methyl 2-(1-{2-[(4-{[...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645438(US20240018122, Example 102 | methyl 2-(1-{2-[(4-{[...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645439(US20240018122, Example 104 | N-(4-{[6-(5-chloro-2-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645440(US20240018122, Example 105 | methyl N-[2-(4-{2-[(4...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645441(US20240018122, Example 106 | N-(4-{[6-(5-chloro-2-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645442(US20240018122, Example 107 | methyl N-[2-(4-{[(4-{...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645443(US20240018122, Example 108 | 2-[4-(2-aminoethyl)pi...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645444(US20240018122, Example 109 | methyl N-[2-(4-{[(4-{...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645428(US20240018122, Example 91 | methyl 4-{2-[(4-{[6-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645429(US20240018122, Example 92 | 4-(3-((4-((6-(5-chloro...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645430(US20240018122, Example 93 | N-(4-{[6-(5-chloro-2- ...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645431(US20240018122, Example 94 | methyl 4-{2-[(4-{[6-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645432(US20240018122, Example 95 | 4-{2-[(4-{[6-(5-chloro...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645433(US20240018122, Example 96 | methyl 2-(4-{[(4-{[6-(...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645434(US20240018122, Example 97 | methyl 2-(4-{2-[(4-{[6...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645435(US20240018122, Example 98 | methyl 2-(4-{2-[(4-{[6...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645436(US20240018122, Example 99 | methyl 1-{2-[(4-{[6-(5...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645437(US20240018122, Example 101 | methyl 2-(1-{2-[(4-{[...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645438(US20240018122, Example 102 | methyl 2-(1-{2-[(4-{[...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645439(US20240018122, Example 104 | N-(4-{[6-(5-chloro-2-...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

TargetTGF-beta receptor type-1(Human)
Chiesi Farmaceutici

US Patent
LigandPNGBDBM645440(US20240018122, Example 105 | methyl N-[2-(4-{2-[(4...)
Affinity DataIC50: 1nMAssay Description:The enzymatic activity of compounds of the present invention was monitored measuring the formation of ADP using the ADP-GLO Kinases assay. Following ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 226 total ) | Next | Last >>
Jump to: